INR 18.99
(-0.05%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Cash Flow | 284 Thousand | -80 Thousand | 708 Thousand | 1.71 Million | -324 Thousand |
Net Income | 14.11 Million | -1.61 Million | -3.64 Million | -7.25 Million | -6.54 Million |
Depreciation & Amortization | 1.91 Million | 2.33 Million | 2.39 Million | 2.19 Million | 2.87 Million |
Deferred income taxes | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - |
Change in working capital | -14.63 Million | -762 Thousand | 1.99 Million | 6.8 Million | 3.39 Million |
Other non-cash items | -1.1 Million | -38 Thousand | -37 Thousand | -40 Thousand | -43 Thousand |
Investing Cash Flow | 300 Thousand | 38 Thousand | -694 Thousand | -1.61 Million | 42 Thousand |
Investments in PPE | - | - | -731 Thousand | -1.65 Million | - |
Acquisitions | - | - | - | - | - |
Investment purchases | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - |
Other Investing Activities | 300 Thousand | - | 37 Thousand | 39 Thousand | - |
Financing Cash Flow | - | - | - | - | - |
Debt repayment | - | - | - | - | - |
Dividends payments | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - |
Other Financing Activities | - | - | - | - | - |
Accounts receivables | -1.96 Million | - | - | - | - |
Accounts payables | - | - | - | - | - |
Inventory | - | - | - | 157 Thousand | 4.52 Million |
Other working capital | -12.66 Million | - | - | 6.65 Million | -1.13 Million |
Cash at beginning of period | 239 Thousand | 281 Thousand | 267 Thousand | 173 Thousand | 455 Thousand |
Cash at end of period | 823 Thousand | 239 Thousand | 281 Thousand | 267 Thousand | 173 Thousand |
Capital Expenditure | - | - | -731 Thousand | -1.65 Million | - |
Effect of forex changes on cash | - | - | - | - | - |
Net cash flow / Change in cash | 584 Thousand | -42 Thousand | 14 Thousand | 94 Thousand | -282 Thousand |
Free Cash Flow | 284 Thousand | -80 Thousand | -23 Thousand | 55 Thousand | -324 Thousand |
Breakdown | 2023 FY | 2022 FY | 2021 FY | 2020 FY | 2019 FY |
---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - |
Net Income | 14.11 Million | -1.61 Million | -3.64 Million | -7.25 Million | -6.54 Million |
Depreciation & Amortization | 1.91 Million | 2.33 Million | 2.39 Million | 2.19 Million | 2.87 Million |
Deferred income taxes | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - |
Change in working capital | -14.63 Million | -762 Thousand | 1.99 Million | 6.8 Million | 3.39 Million |
Other non-cash items | -1.1 Million | -38 Thousand | -37 Thousand | -40 Thousand | -43 Thousand |
Investing Cash Flow | 300 Thousand | 38 Thousand | -694 Thousand | -1.61 Million | 42 Thousand |
Investments in PPE | - | - | -731 Thousand | -1.65 Million | - |
Acquisitions | - | - | - | - | - |
Investment purchases | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - |
Other Investing Activities | - | - | 37 Thousand | 39 Thousand | - |
Financing Cash Flow | - | - | - | - | - |
Debt repayment | - | - | - | - | - |
Dividends payments | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - |
Other Financing Activities | - | - | - | - | - |
Accounts receivables | - | - | - | - | - |
Accounts payables | - | - | - | - | - |
Inventory | - | - | - | 157 Thousand | 4.52 Million |
Other working capital | - | - | - | 6.65 Million | -1.13 Million |
Cash at beginning of period | 239 Thousand | 281 Thousand | 267 Thousand | 173 Thousand | 455 Thousand |
Cash at end of period | 823 Thousand | 239 Thousand | 281 Thousand | 267 Thousand | 173 Thousand |
Capital Expenditure | - | - | -731 Thousand | -1.65 Million | - |
Effect of forex changes on cash | - | - | - | - | - |
Net cash flow / Change in cash | 584 Thousand | -42 Thousand | 14 Thousand | 94 Thousand | -282 Thousand |
Free Cash Flow | 284 Thousand | -80 Thousand | -23 Thousand | 55 Thousand | -324 Thousand |
JAL
MEDICAMEQ
OGN
VBX
8159
FEVR